Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for dermatological disorders and other significant medical needs. The company focuses on conditions such as eczema, chronic wounds, psoriasis, asthma, and acne. Utilizing their proprietary BioLexa Platform, Hoth Therapeutics aims to create two topical cream products to treat eczema and reduce post-procedure infections in aesthetic dermatology patients.
Hoth Therapeutics has established numerous license and partnership agreements with prestigious institutions including The George Washington University, The University of Maryland Baltimore, Isoprene Pharmaceuticals, Inc., North Carolina State University, Chelexa Biosciences, Inc., The University of Cincinnati, and Zyla Therapeutics, Inc. Notably, Hoth is co-developing a topical treatment with Zyla Therapeutics for cutaneous lupus erythematosus, an autoimmune disease that severely impacts patient quality of life.
The company’s research collaborations extend to various areas including HT-001, a potential treatment for cancer patients experiencing skin toxicities from Epidermal Growth Factor Receptor Inhibitors (EGFRI). Hoth has recently received FDA clearance to proceed with protocol amendments in its ongoing Phase 2a clinical trials for HT-001, aiming to optimize clinical outcomes.
Hoth Therapeutics has also made strides in Alzheimer's Disease research with its HT-ALZ project, targeting neuroinflammation and cognitive deficits by antagonizing the NK1 receptor. Pre-clinical research has shown promising results in improving cognitive functions among Alzheimer's patients.
In addition to their pipeline, Hoth's subsidiary Merveille.ai has been pivotal in advancing obesity treatment using artificial intelligence. The discovery of a promising new therapeutic candidate for obesity, leveraging large language model technologies, underscores their commitment to innovative health solutions.
Financially, Hoth Therapeutics recently engaged in an agreement to exercise warrants, raising approximately $4.2 million to support its working capital needs. Their strategic partnership with Venable, LLP further strengthens their intellectual property protection, vital for ongoing and future therapeutic developments.
Collaborations with Wise Systems International SRL and integration of the Nvidia BioNeMo AI platform are set to enhance Hoth's drug discovery capabilities, leveraging artificial intelligence for cutting-edge therapeutic advancements.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a definitive agreement for a private placement of 7,594,937 shares of common stock and warrants to purchase the same number of shares at $1.975 each, expected to yield approximately $15 million. The placement is set to close around March 10, 2021. The gross proceeds will fund the development of Hoth's product candidates and general corporate purposes. The warrants will have an exercise price of $1.86 and a three-year term.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced progress on its preclinical study for HT-002, a peptide therapeutic aimed at preventing or treating COVID-19. Conducted at Virginia Commonwealth University, the study has identified three optimized peptide candidates that may inhibit the SARS-CoV-2 virus, with one showing low viral inhibition and no toxicity. The peptides are believed to be effective against emerging virus variants, and further in vitro testing is underway. Hoth continues to support this research through funding agreements with VCU.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has successfully completed recruitment for Cohort 1 of its first-in-human clinical trial using the BioLexa platform to treat atopic dermatitis (eczema). CEO Robb Knie emphasized the unmet need for effective topical therapies for mild to moderate eczema patients. The company is optimistic about revealing preliminary trial results later this year. Hoth's focus is on developing therapies for various medical conditions, including skin toxicities and COVID-19 treatment prospects.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has expanded its licensing agreement with North Carolina State University to globally develop treatments for mast cell-derived cancers and anaphylaxis. The new therapy, HT-KIT, targets the KIT receptor linked to several cancers and severe allergic reactions. Initial proof-of-concept data supports its effectiveness, with a focus on aggressive mast cell neoplasms. Hoth aims to address critical unmet patient needs and enhance its therapeutic pipeline through this strategic collaboration.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has engaged RedChip Companies, Inc. to enhance its investor relations efforts. RedChip, a leader in investor relations for microcap stocks, aims to leverage its extensive network to help Hoth achieve its capital market objectives. Hoth focuses on developing therapies for unmet medical needs, including conditions like atopic dermatitis and COVID-19. The company is positioned to improve patient quality of life through innovative treatments.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has filed a provisional patent application for a therapeutic aimed at treating and preventing Alzheimer's disease, marking a significant development in its portfolio. Alongside this, the company has secured an exclusive license for the drug's use in other indications. Alzheimer's disease is a major public health concern, projected to triple in prevalence by 2050. Hoth is a clinical-stage biopharmaceutical company focused on innovative treatments for various health conditions.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the successful completion of a pre-IND meeting with the FDA regarding their HT-001 product, aimed at treating skin disorders linked to EGFR inhibitor therapy. Key FDA feedback included approval of the proposed formulation, the appropriateness of the planned indications upon further data, and details on the IND-enabling toxicology program for a phase 2a study. This positive outcome supports Hoth's plans to advance its clinical development for HT-001, a significant milestone for the company in addressing cancer-related dermatological issues.
Hoth Therapeutics (NASDAQ: HOTH) announced plans to expand its HT-003 active pharmaceutical ingredient (API) development to target inflammatory bowel diseases (IBDs) like Crohn's disease and ulcerative colitis. This initiative follows an option agreement with Isoprene Pharmaceuticals to study HT-003's potential as an IBD treatment. Current research shows HT-003 may possess anti-inflammatory properties, which Hoth intends to explore further using ex vivo and in vitro studies. The company aims to address significant patient needs in this area.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced its participation in the Diamond Equity Research Growth Invitational virtual investor conference on February 24, 2021. The event will take place at 9:40 a.m. ET and will include a presentation followed by a Q&A session. Hoth Therapeutics is focused on developing new therapies for unmet medical needs, targeting conditions such as atopic dermatitis and chronic wounds, with ongoing projects related to COVID-19. For more information, visit Hoth's Investor Relations.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that Scientific Advisory Board member Michael Peter, Ph.D., published a whitepaper in bioRxiv focusing on COVID-19 SARS-CoV-2. The study utilizes computational modeling to analyze protein-protein binding interactions critical for viral entry, particularly regarding mutations in emerging variants. Hoth has previously secured a licensed agreement for peptide therapeutics targeting this interface to aid in COVID-19 treatment, with research guided by Dr. Peter. This work supports the development of therapeutic candidates against SARS-CoV-2 variants.
FAQ
What is the current stock price of Hoth Therapeutics (HOTH)?
What is the market cap of Hoth Therapeutics (HOTH)?
What is Hoth Therapeutics, Inc.?
What conditions does Hoth Therapeutics focus on?
What is the BioLexa Platform?
Who are some of Hoth Therapeutics' partners?
What is HT-001?
What recent advancements have been made in Alzheimer's Disease research by Hoth Therapeutics?
How is Hoth Therapeutics advancing obesity treatment?
What financial actions has Hoth Therapeutics recently taken?
What is the significance of Hoth Therapeutics' partnership with Venable, LLP?
How is artificial intelligence being used by Hoth Therapeutics?
